Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Mouse (Murine) PLAUR Protein expressed in Human Cells - ABIN2007425
Dear, Medcalf: The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule. in European journal of biochemistry / FEBS 1998
Show all 3 Pubmed References
Human PLAUR Protein expressed in HEK-293 Cells - ABIN2713801
Ge, Siegel, Jordan, Naumann: Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures. in Biophysical journal 2014
The synergy of circulating factor suPAR and APOL1 (show APOL1 Proteins) G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD.
Results identify soluble uPAR as a functional connection between the bone marrow and the kidney, and they implicate bone marrow immature myeloid cells as a key source of soluble uPAR that leads to glomerular dysfunction.
Plaur deficiency does not increase susceptibility to epileptogenesis after traumatic brain injury in an animal model.
Significance of the urokinase-type plasminogen activator (show PLAU Proteins) and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Findings indicate a significant correlation of uPAR cleavage with breast cancer progression, but the precise biological consequence(s) of the cleavage or the cleavage products still remains to be elucidated.
interaction of full-length suPAR with alphavbeta3 integrin expressed on podocytes results in down-modulation of nephrin (show NPHS1 Proteins) that may affect kidney functionality in different human pathologies characterized by increased concentration of suPAR.
In an in vivo murine angiogenesis model uPAR-deficient PTEN heterozygous animals increased the impaired angiogenic phenotype of uPAR knockout mice and were able to reverse the high invasive potential of PTEN heterozygotes.
uPAR contributes to macrophage driven atherosclerotic lesion formation.
we have firstly shown a fundamental mechanism of urokinase system(uPa (show PLAU Proteins) and uPAR)-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
our data show that uPAR is required for efficient skin tumor formation
Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA (show PRAP1 Proteins) and IGF1R (show IGF1R Proteins).
PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1 (show CHEK1 Proteins)); maintenance of cell cycle arrest after DNA damage in a TP53 (show TP53 Proteins)-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 (show RAD51 Proteins) recombinase (show RAG1 Proteins), the principal protein involved in the homologous recombination repair pathway.
Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP (show CRP Proteins)) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP (show CRP Proteins)
This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS (show JAG1 Proteins) cells, is mediated by the EP2 receptor-dependent Src (show SRC Proteins)/EGFR (show EGFR Proteins)/JNK1 (show MAPK8 Proteins)/2, Erk1/2/AP-1 (show FOSB Proteins), and Src (show SRC Proteins)/EGFR (show EGFR Proteins)/JNK1 (show MAPK8 Proteins)/2, Erk1/2/NF-kappaB (show NFKB1 Proteins) cascades.
Studies indicate the feasibility of combining two U-PA (show PLAU Proteins) receptor (uPAR)-targeted probes in a preclinical head and neck cancer model.
soluble urokinase plasminogen activator receptor was associated with low left ventricular ejection fraction and elevated BNP.
Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis.
results show that the uPA (show PRAP1 Proteins)/uPAR/LRP1 (show LRP1 Proteins) system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury
our study indicates that suPAR increases in patients with AML (show RUNX1 Proteins) and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML (show RUNX1 Proteins) and may help in the developing of specific therapeutic targets.
Data show that urokinase-type plasminogen activator (uPA (show PLAU Proteins)) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA (show PLAU Proteins) receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Proteins)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA (show PLAU Proteins)/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
Data indicate that superoxide dismutase (SOD) inhibited high glucose (HG)-induced expression of uPAR and VEGF in bovine retinal microvascular endothelial cell (REC).
These data indicated that E. coli LPS (show IRF6 Proteins) led to an increase in u-PA (show PLAU Proteins) activity and RNA expression of u-PA (show PLAU Proteins) and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
the interaction between uPAR and Man-6-P/IGF2R (show IGF2R Proteins) is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/IGF2R (show IGF2R Proteins) by different mechanisms.
This gene encodes the receptor for urokinase plasminogen activator and, given its role in localizing and promoting plasmin formation, likely influences many normal and pathological processes related to cell-surface plasminogen activation and localized degradation of the extracellular matrix. It binds both the proprotein and mature forms of urokinase plasminogen activator and permits the activation of the receptor-bound pro-enzyme by plasmin. The protein lacks transmembrane or cytoplasmic domains and may be anchored to the plasma membrane by a glycosyl-phosphatidylinositol (GPI) moiety following cleavage of the nascent polypeptide near its carboxy-terminus. However, a soluble protein is also produced in some cell types. Alternative splicing results in multiple transcript variants encoding different isoforms. The proprotein experiences several post-translational cleavage reactions that have not yet been fully defined.
urokinase plasminogen activator surface receptor
, plasminogen activator, urokinase receptor
, urokinase plasminogen activator receptor
, urokinase-type plasminogen activator receptor
, monocyte activation antigen Mo3
, u-plasminogen activator receptor form 2
, urokinase-type plasminogen activator (uPA) receptor
, plasminogen activator urokinase receptor 3
, urinary plasminogen activator receptor 2
, urinary plasminogen activator receptor 3